Regulations and compliance · Practical guide

ICH E6(R3) sponsor oversight of outsourced trial data

Under ICH E6(R3), sponsor oversight keeps responsibility, information and decisions connected when clinical trial activities are outsourced. A contract with a data management or system provider does not automatically transfer the sponsor's overall responsibility. A data processing example shows how to organise handovers and focus oversight on important activities and actual risks.

Table of contents

At a glance

What remains the sponsor’s responsibility when a provider processes trial data?

A sponsor may transfer trial activities to suitable providers but retains overall responsibility for participant protection and reliability of trial data. Agree the tasks, evidence, information flows and handling of changes and problems. Oversight should cover important activities and relevant subcontractors. Base it on a justified assessment of suitability and actual evidence coverage. It does not require repeating all supplier tests.

  • Explicitly state transferred responsibilities and remaining decisions.
  • Ensure access to relevant evidence regarding the service provider chain.
  • Oversight of key activities, data impact, and effective response.

1. Use the currently applicable GCP foundation

This article concerns clinical trials of human medicines. ICH E6(R3) Principles and Annex 1 have applied in the EU since 23 July 2025. At the source check on 7 October 2026, Annex 2 had been adopted, with an EU effective date of 15 January 2027. A later consolidated file does not make every provision immediately applicable.

The EMA guidelines on computerised systems and electronic data from 2023 extend the specific considerations regarding systems, agreements, and data access. GMP Annex 11 is not a blanket requirement under GCP. Similarly, no universal clinical trial or retention periods are derived herein. The relevant factors remain the specific study protocol and applicable requirements.

Sources: [1] [2] [3]

2. Assign tasks with clear boundaries

ICH E6(R3) Annex 1 Section 3.6 outlines agreements among parties and the management of third-party services. Transferred activities shall be clearly defined. Any activities not explicitly transferred remain the responsibility of the sponsor. The overarching sponsor responsibility for participant rights, safety, welfare, and data integrity remains intact.

Therefore, attribute results to specific responsibilities rather than merely departmental names. "External data management" leaves open questions regarding who defines rules, evaluates anomalies, authorizes changes, and transfers data. An agreement should clarify these handoffs. Tasks that fall under the reviewer's responsibility are not automatically converted into sponsor responsibilities solely by virtue of a sponsor agreement.

Sources: [2]

3. Link task, decision, and evidence

The example matrix illustrates a service provider responsible for transferring laboratory results to a study database. It does not represent a universal role assignment. The specific responsibilities must align with the study and agreed arrangements. It is crucial that no decision-making responsibility is lost at any interface between two parties.

Also arrange for access to relevant system and study validation records. A mere assurance that the product is validated does not address the study-specific questions regarding configuration, interfaces, and changes. Appropriate supplier validation records may contribute, provided their actual scope is assessed.

Example: internal transfer matrix for outsourced data import
TaskDecision to makeEvidence neededinformation pathway
Configure import Which fields and units apply in the protocol? Coordinated Assignment and Appropriate Testing Accountable party to supplier and back
Operate import How are missing or inconsistent data sets identified? Comparison and documented error handling Supplier reports relevant findings
Change configuration Which historical and new data are affected? Impact assessment and appropriate evidence Agree the change before activation
Transfer hosting responsibility What important activity does the next position take? Appropriate assessment and access to evidence Primary supplier makes relevant data sharing visible
End the study Who receives which usable data? Complete, clear handover as agreed The sponsor and trial site each receive the outputs they need

Sources: [2] [3]

4. Assess the actual suitability of the service provider

The selection should align with the assigned responsibilities. Assess the supplier’s knowledge, processes, and relevant experience or evidence. Not every activity requires the same evaluation approach. A blanket requirement for on-site, full audits of every technical supplier is not derived therefrom.

Important are robust responses to specific questions: Can the supplier maintain the study-specific configuration? Are relevant documentation accessible? Are critical issues communicated promptly? If required agreements and traceability access cannot be assured, this constitutes a material suitability issue. General certificates may provide information, but they do not substitute for task-specific evaluation.

Sources: [2] [3]

5. Example: Quantity reconciliation alone is insufficient

In this example, the supplier is responsible for transferring 24 laboratory records. During the planned reconciliation, 24 lines appear in the study database, but record L-08 was imported twice and record L-19 is missing. While the line count is correct, the number of unique records is only 23. Therefore, appropriate oversight must understand the significance of the reconciliation process. In this case, it is agreed that the sponsor receives a count report and relevant import deviations. The monthly report shows 24 lines without any indication of the issue; the duplicate and missing record are only noted in an internal exception report prepared by the service provider. Thus, both the data error and the agreed information pathway must be assessed.

The sponsor is not required to technically re-import each dataset individually. Instead, a robust control mechanism and an information pathway that makes the findings visible and enables appropriate decision-making are necessary. The specific actions required depend primarily on the significance of the affected data for participants and study outcomes.

Example: completed Oversight Matrix
Control stepExpected and observed state in the exampleAssessmentExpected reaction
Quantity 24 expected, 24 lines present No mere completeness confirmation Compare identities and assignments additionally.
Identity L-08 appears twice, L-19 is missing 23 unique records instead of 24 Investigate the root cause and identify the affected transfer.
Data impact Significance of L-19 initially open Do not automatically classify the finding as minor or serious Assess how the change affects trial participants and the analysis.
Action Corrected transfer intended Success only achieved after appropriate alignment Document the cause, correction, and verified status
Oversight The internal exception report was not provided to the sponsor. The quantity report does not enable the required decision. Retrieve the report, correct the information pathway, and verify its effectiveness through an appropriate controlled reporting mechanism.

Sources: [2] [3]

6. Maintain oversight of important activities that are subcontracted

Sponsor oversight can extend beyond the immediate contractor. ICH E6(R3) includes important activities the contractor delegates to other service providers. Identify further delegation that can affect data flow, availability or important records, and assess the significance of each provider.

Arrange for appropriate information regarding relevant changes and access to required documentation. When transitioning to a new hosting or data processing service, the application itself may remain externally unchanged, while data access and responsibilities may shift. Oversight should be able to identify such impacts, rather than relying solely on unchanged screen functions.

Sources: [2] [3]

7. Turn metrics into actionable oversight

A low number of open tickets does not automatically indicate a controlled process. Assess which issues are captured, their significance, and whether recurring patterns are evident. A small number of serious findings may be more critical than numerous minor operational queries.

Define which information is required immediately and which is to be jointly evaluated on a regular basis. The form and frequency should align with the key risks. The specific response may include a data correction, additional inspection, amendment to the agreement, or restriction of usage. A universal interval or full repetition of all supplier tests is not prescribed here.

Sources: [2] [3]

Further reading:

8. Checklist for Robust Sponsor Oversight

Compile the agreement, technical evidence, and actual operational information. A good agreement alone does not demonstrate that alerts are received and corrective actions are completed. Conversely, an engaged operational team cannot permanently compensate for missing access rights or unclear decision authority.

The following internal guidance document supports implementation. It is not a complete contract template and does not constitute a comprehensive list of all GCP obligations. Its focus lies on the controlled transfer and oversight of key data processing tasks.

  • Explicitly defined transferred activities and remaining responsibilities.
  • The supplier's suitability with respect to the specific tasks is assessed.
  • Appropriate system and study validation evidence is available.
  • Important subcontracted activities and change procedures are identified.
  • Reports shall include professionally relevant contextual information.
  • Supervision and responses focused on key risk areas.
  • Data transfer, exit, and continued access are practically governed.

Sources: [2] [3]

Project experience and collaboration

Use service provider reports to support sponsor oversight

With the sponsor team, we examine a specific report and associated deviation involving system or data activities. What reaches the sponsor, who evaluates it and when is a decision needed? Where evidence exists, clearer reports and escalation routes may suffice. If an important outsourced activity lacks visibility, we identify the extra information or assessment required. We help provide the basis for oversight. The sponsor retains responsibility.

Frequently asked questions about ICH E6(R3) sponsor oversight of outsourced trial data

Can the Sponsor delegate its overall responsibility to a CRO?

It can delegate activities, but retains overall responsibility for participant rights, safety, welfare, and data reliability under ICH E6(R3). Agreements must clearly define tasks. Complete transfer of responsibility does not follow from the outsourcing contract.

Sources: [2]

What happens to activities that are not explicitly transferred?

Section 3.6 confirms that activities not explicitly transferred remain with the sponsor. Therefore, agreements should specify concrete outcomes and handover responsibilities. A general statement such as "the supplier is responsible for data management" may leave critical decisions and documentation requirements unaddressed.

Sources: [2]

Must the Sponsor perform each supplier test itself?

Not at all. Suitable existing evidence can contribute to the assessment. Check their actual coverage for system, configuration, interface and study. Any remaining questions need to be handled appropriately; the responsibility will not be given by taking over documents.

Sources: [2] [3]

Are ISO certificates sufficient for supplier selection?

You can provide relevant information, but you cannot automatically address all study-specific questions. Assess the transferred responsibilities, processes, and required documentation. Crucially, it must be determined whether the supplier can reliably support the specific activity in accordance with the applicable requirements.

Sources: [2] [3]

Must subcontractors be considered?

Key downstream activities fall within the scope of oversight. Assess their impact on data, processes, and traceability. This does not imply that every technical supplier must undergo identical evaluation. The extent and nature of the assessment should be commensurate with the significance of the activity.

Sources: [2] [3]

Why are the number of imported data sets insufficient?

Equal line counts can mask duplicates and missing identities. In the example of this article, 24 lines represent only 23 unique records. An appropriate reconciliation must evaluate completeness and assignment relevant to the study, not merely compare total line counts.

Sources: [2] [3]

How frequently must an Oversight Meeting take place?

ICH E6(R3) does not specify a fixed general frequency. The scope and nature of oversight should be tailored to the complexity and risks associated with the study (3.9.5); issues should be appropriately escalated and further tracked promptly (3.9.6). Therefore, an immediate response is not to be delayed until the next regulatory review period. Regular evaluations and specific additional triggers should be established.

Sources: [2]

Can a supplier completely withhold critical documentation?

This may preclude usage. If, due to the supplier's lack of capability or willingness, appropriate agreements granting access to critical documentation cannot be established, or if the supplier does not support pre-selection or regulatory inspection audits, their systems shall not be used in clinical trials, in accordance with the EMA Guideline 2023 (Annex 1 "Agreements"). Therefore, these rights must be clarified prior to contract signing. ICH E6(R3) 3.6.8 addresses access to information required by the sponsor for selection and oversight.

Sources: [3]

Does Annex 2 of ICH E6(R3) come into effect in October 2026?

The EMA lists 15 January 2027 as the planned EU effective date. The Principles and Annex 1 have applied since 23 July 2025. Distinguish availability of the document from its date of application.

Sources: [1]

Is Sponsor Oversight the same as GMP Supplier Assessment?

There are similar operational questions, but distinct regulatory contexts. This article addresses Human Medicinal Product-GCP. GMP Annex 11 and general supplier procedures cannot be unconditionally considered a complete GCP foundation; the evaluation must be based on the specific study, responsibilities, and applicable requirements.

Sources: [2] [3]

Sources and review date

Source date: 7 October 2026. Regulatory requirements, guidelines, and industry practices must be categorized separately. Tables, figures, and case examples are to be considered standalone reference materials; they do not constitute completed product testing.

  1. EMA: Status ICH E6 Good Clinical PracticeAs of 07.10.2026: Principles/Annex 1 in force; Annex 2 to become effective from 15.01.2027.
  2. EMA: ICH E6(R3), Principles and Annex 1Principles and Annex 1; in force in the EU since 23.07.2025.
  3. EMA: Computerised Systems and Electronic Data in Clinical TrialsEMA/INS/GCP/112288/2023, 09.03.2023; Guidelines for clinical trials.

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Jointly develop the specific evidence process

We support sponsors, Clinical Data Management, and IT in practically shaping the service chain, audit trail access, and key transfer decisions.

  • Cloud and SaaS validation →

    Maintain the validated state of cloud and SaaS systems as suppliers issue new versions. We define the boundary between your responsibilities and the supplier’s and agree how each release will be assessed.

Send a project enquiry Customer testimonials →